SITC 2025 Poster #352

Preclinical Evaluation of an IO Therapy Using TME Assays in a 3D High Content Imaging Platform

Ezgi Kaya Aksoy, Sander Basten, Saskia de Man, Lois Van der Drift, Emma Spanjaard, Gera Goverse and Nataliia Beztsinna

Discover how high-content imaging and TME-based 3D models enable deeper insights into γδ T cell–driven tumor killing and immune interactions.

Traditional in vitro assays often fail to capture the complexity of tumor–immune interactions that define real clinical response. In this study, Crown Bioscience demonstrates how 3D high-content imaging (HCI) and ex vivo patient tissue assays deliver a scalable and biologically relevant platform for preclinical immuno-oncology evaluation. Using both reconstituted and native tumor microenvironments (TME), our approach reveals how engineered γδ T cells drive targeted tumor killing and infiltration in ovarian cancer models — bridging the gap between mechanistic insight and translational predictivity.

Download this Poster to Discover:

• Compare 3D model types: See how reconstituted co-cultures and native ex vivo tumor platforms differ in scalability and physiological relevance.
  
  
• Evaluate T cell activity: Examine how γδ T cells induce tumor killing across both OVCAR-3 spheroid and patient-derived tumor tissues.
  
  
• Visualize complex immune interactions: Explore high-content imaging results that reveal infiltration, activation, and tumor volume changes in 3D assays.
  
  
• Select the right TME model for your study: Understand how assay choice impacts throughput, reproducibility, and biological accuracy in IO research.

Download the Poster Now!